Barw Barw Medical Journal 2960-1959 2024 06 29 Effect of Sunitinib in the Management of Lung Cancer: A Systematic Review of Clinical Trials 10.58742/bmj.v2i2.95 eng Rebaz M. Ali Hiwa Cancer Hospital, Sulaimani Directorate of Health, Sulaymaniyah, Kurdistan, Iraq. rebaz.ali@gmail.com Sami S. Omar Rizgary Oncology Center, Peshawa Qazi Street, Erbil, Kurdistan, Iraq. sami.omar@gmail.com Fahmi H. kakamad College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. fahmi.hussein@univsul.edu.iq Harem K. Ahmed Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. harem23@gmail.com Diyar A. Omar Medical Laboratory Technology, Shaqlawa Technical College, Erbil Polytechnic University, Erbil, Kurdistan, Iraq. diyar.omar@gmail.com Yousif M. Mahmood Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. yousif.mahmood@gmail.com Mohammed Q. Mustafa Department of Medical Analysis, Tishk International University, Erbil, Kurdistan, Iraq . mohammed.mustafa@gmail.com Aland S. Abdullah College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. aland.abdullah@gmail.com Marwan N. Hassan Kscien Organization for Scientific Research (Middle East Office), Hamid Street, Azadi Mall, Sulaymaniyah, Kurdistan, Iraq. marwan.hassan@gmail.com Dahat A. Hussein Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. dahat.hussein@gmail.com Suhaib H. Kakamad Collage of Medicine, Department of Immunology and Hematology, Kurdistan University of Medical Science, Sanandaj, Iran. suhaib.kakamad@gmail.com Hiwa O. Abdullah Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. hiewaom96@gmail.com Hawbash M. Rahim Department of Medical Laboratory Science, College of Health Sciences, University of Human Development, Kurdistan Region, Sulaymaniyah, Iraq. hawbash.mhamad96@gmail.com Berun A. Abdalla Department of Biology, College of Education, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq. berun.anwer95@gmail.com Shvan H. Mohammed Xzmat Polyclinic, Rizgari, Kalar, Sulaymaniyah, Kurdistan, Iraq. shvan.mohammed@gmail.com 2024 04 15 Introduction Lung cancer is the most common cancer in terms of both incidence and mortality. Although usually managed with surgery, novel immunotherapies are gradually becoming more popular. The effect of sunitinib with and without erlotinib in the management of lung cancer is reviewed. Methods Eligible search engines and databases were screened to identify studies published in English. Any randomized clinical trials studying the effect of sunitinib, either alone or in combination with erlotinib, were included. Results Thirteen studies with a total sample size of 1,062 cases were included. Males (59.5%) were more common than females (40.5%), and the average age of patients was 64 ± 5.03. Most of the patients (71.5%) had a positive smoking status, and non-small cell carcinoma was the most common lung cancer type (95.4%). Almost all of the adverse events, such as headache (100%), weight loss (100%), constipation (100%), leukocytopenia (96%), pain (92.3%), hypertension (90%), dyspnea (88.7%), cough (84.3%), fatigue (81.6%), fever/chills (77.3%), thrombocytopenia (75%), nausea (73.8%), neutropenia (72%), anorexia (71.4%), vomiting (65.1%), anemia (61.3%), and diarrhea (54.5%) were more common in the sunitinib-only group. The mean overall survival for patients receiving sunitinib alone was 213 days, whereas, for patients receiving sunitinib combined with erlotinib, it was 270 days. Conclusion Adverse events may be encountered more frequently in treatment with sunitinib alone compared to the combination of sunitinib and erlotinib. However, sunitinib alone may result in higher disease stability and lower disease progression. Nevertheless, combination therapy may yield a longer median overall survival.